
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management
Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Advertisement
Video content above is prompted by the following:
How did you develop your administration and adverse event monitoring and management protocols?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Community Clinical Trials and the Lung Cancer Pipeline
2
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
3
Dr Erica Stringer-Reasor on Gedatolisib's FDA Approval in Breast Cancer
4
Navigating CAR T Decision-Making in R/R DLBCL
5





















